Loading…
IRON
Disc Medicine, Inc.
NASDAQ· Healthcare· Biotechnology
$80.03-3.05%
Key metrics
- Market cap
- $3.07B
- P/E
- —
- Forward P/E
- —
- P/B
- 4.8x
- Dividend yield
- —
- EPS
- -$6.38
- ROE
- -39.08%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 2.06
- 52-week high
- $99.50
- 52-week low
- $40.00
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
- 165
- Watertown, United States
Company description provided by Yahoo Finance.